Türkiye to begin domestic production of key SMA drug
Türkiye has announced that it will begin producing the active ingredient of a major spinal muscular atrophy (SMA) treatment and the production of the drug domestically, marking a significant step toward reducing dependence on costly imported therapies for the rare genetic disease.
